Immuneel Therapeutics launches Qartemi, a CAR T-cell therapy for Non-Hodgkin’s Lymphoma
Immuneel has collaborated with hospitals including Narayana Health, Apollo Hospitals, CMC Vellore, Manipal Hospitals among others…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CAR-T cell therapy
Aurigene Oncology announces phase 1 results for India’s first CAR-T cell therapy in multiple Myeloma
SWASTH study reports clinical response in all patients; Drugs Controller General of India approves Phase 2 trial
Revolutionising cancer treatment: The promise of point-of-care CAR-T therapy
Dr Prudwidhar S, Country Medical Affairs Director, Miltenyi Biotec emphasises why successful implementation of CAR-T cell therapy…
US FDA gives record number of review designations to CRISPR drugs in 2023: GlobalData
Casgevy is the first CRISPR-based drug to receive marketing authorisation globally
ImmunoACT to lead journey of indigenous CAR-T cell therapy in India but market access a hurdle:…
As per ImmunoACT CEO, NexCAR19 will be available at a price of Rs 30-40 lakh ($36,000- $48,000), which is 1/10th of the cost of…
US FDA approves Bristol Myers Squibb’s CAR-T cell therapy Breyanzi for relapsed large B-cell…
In the pivotal phase-III Transform trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of…
Immuneel sets up cell therapy development and production facility in Narayana Hrudayalaya Health…
The facility will currently focus on autologous cell therapies including CAR-T cell therapy for lymphomas and leukaemias